Accessibility Menu
Anixa Biosciences logo

Anixa Biosciences(NASDAQ) ANIX

Market Cap$118.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1984)-93%
5 Year-21%
1 Year+12%
1 Month+22%
$3.45
-0.86%
-0.03Today
Anixa Biosciences last closing stock price
MetricPriceDate
Last closeUSD 3.482026-07-29
Anixa Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.14%USD 3.522026-07-22
1 month+22.11%USD 2.852026-06-29
3 month+16%USD 3.002026-04-30
Year to date+11.54%USD 3.122025-12-31
1 year+12.26%USD 3.102025-07-29
3 year-4.13%USD 3.632023-07-28
5 year-21.27%USD 4.422021-07-30
Since inception-92.86%USD 48.751984-05-15

Anixa Biosciences Financials at a Glance

Market Cap

$118.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.07M

EPS (TTM)

-$0.30

P/E Ratio

-11.48

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$3.45

Volume

126,350.469

Open

$3.48

Previous Close

$3.56

Daily Range

$3.40 - $3.58

52-Week Range

$2.32 - $5.46

Estimated Earnings Date

Sep 10, 2026

ANIX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Anixa Biosciences

Anixa develops new therapies and vaccines for cancer and infectious diseases. Its work aims to help patients facing breast and ovarian cancer. The company partners with research centers to advance early-stage treatments.

What’s in the Anixa Toolbox?

  • Cancer Vaccines: Preventive vaccines for breast and ovarian cancer; 0% of 2024 revenue.
  • CAR-T Therapeutics: Cell-based therapy for ovarian cancer; 0% of 2024 revenue.
  • Early-Stage Cancer Vaccines: Research for lung, colon, and prostate cancer vaccines; 0% of 2024 revenue.
  • Anti-Viral Drug Discovery: COVID-19 drug research; 0% of 2024 revenue.
  • Legacy Patent Licensing: Occasional income from old technology patents; 0% of 2024 revenue.

Growth and Expansion: The Anixa Adventure

  • 2018: Changed name from ITUS to Anixa, focusing on cancer and infectious disease therapies.
  • Ongoing: Collaborations with Cleveland Clinic, The Wistar Institute, and H. Lee Moffitt Cancer Center for vaccine and therapy development.
  • 2024: Joint agreement with Cleveland Clinic to develop vaccines for lung, colon, and prostate cancers.
  • 2024: Expanded clinical trial programs for breast and ovarian cancer vaccines.
  • No major acquisitions or global market entries reported in recent years.

What Makes Anixa Stand Out?

Anixa focuses on early-stage cancer prevention and treatment using unique vaccine and cell therapy approaches. The company leverages exclusive technology licenses from major research institutions. Its business model relies on partnerships to reduce costs and share expertise.

Five Things You Need to Know

  • No product revenue in 2024; all programs are pre-commercial.
  • Operating loss was $13.8 million in fiscal year 2024, up 25.6% from fiscal year 2023.
  • Cash and short-term investments totaled $19.9 million as of October 31, 2024.
  • Only five full-time employees as of late 2024.
  • Accumulated deficit reached $240.8 million by October 2024.

Bottom Line

Anixa is an early-stage biotech focused on cancer vaccines and therapies. Its future depends on clinical progress and continued partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Amit D. Kumar, PhD, MBA

Website

www.anixa.com

Headquarters

San Jose, CA 95118, US

ANIX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-65.73%

Return on Capital

-76.15%

Return on Assets

-67.77%

Earnings Yield

-8.71%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$118.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

34.02M

Volume

126.35K

Avg. Volume

217.85K

Financials (TTM)

Gross Profit

-$9.00K

Operating Income

-$10.68M

EBITDA

-$10.10M

Operating Cash Flow

-$7.12M

Capital Expenditure

$0.00

Free Cash Flow

-$7.12M

Cash & ST Invst.

$13.69M

Total Debt

$184.00K

Anixa Biosciences Performance Analysis

Anixa Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-10-31USD 0N/A
20232023-10-31USD 210,000N/A
20242024-10-31USD 0N/A
20252025-10-31USD 0N/A
Anixa Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-31N/A
Q42025-10-31N/A
Q12026-01-31N/A
Q22026-04-30N/A
Anixa Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-10-31USD -0.45-1.3%
20232023-10-31USD -0.32-29.2%
20242024-10-31USD -0.3924.3%
20252025-10-31USD -0.34-14.5%
Anixa Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-3119.7%
Q42025-10-31-17.4%
Q12026-01-315.4%
Q22026-04-309.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$118.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$29.60M

N/A

Employees

4

N/A

Net Income

-$2.56M

+8.4%

EBITDA

-$2.54M

+9.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$13.69M

-12.3%

Total Debt

$184.00K

-16.7%

Accounts Receivable

$56.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$140.00K

-23.9%

Short Term Debt

$44.00K

+18.9%

Return on Assets

-67.77%

N/A

Return on Invested Capital

-79.88%

N/A

Free Cash Flow

-$1.74M

-15.8%

Operating Cash Flow

-$1.74M

-15.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SEERSeer, Inc.
$2.06-0.96%
HURATuHURA Biosciences, Inc.
$2.17+6.37%
ENTXEntera Bio Ltd.
$2.95-1.67%
ABOSAcumen Pharmaceuticals, Inc.
$2.17+2.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About ANIX

What is the current price of Anixa Biosciences?

Anixa Biosciences is trading at $3.56 per share.

What is the 52-week range for Anixa Biosciences?

Over the past 52 weeks, Anixa Biosciences has traded between $2.32 and $5.46.

How much debt does Anixa Biosciences have?

As of the most recent reporting period, Anixa Biosciences reported total debt of $184.00K.

How much cash does Anixa Biosciences have on hand?

Anixa Biosciences reported $1.48M in cash and cash equivalents in its most recent financial results.

What is Anixa Biosciences’s dividend yield?

Anixa Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services